MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
Milestone Scientific Income Statement 2011-2026 | MLSS
Annual Income Statement Milestone Scientific
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
69.4 M | 45.1 M | 65 M | 88.8 M | 178 M | 80.5 M | 14.1 M | 32.4 M | 33.7 M | 36.6 M | 54.6 M | 25.7 M | 20.1 M | 7.59 M |
Shares |
79.8 M | 72.8 M | 70.6 M | 68.8 M | 63.1 M | 45.7 M | 35.3 M | 32.7 M | 27 M | 21.4 M | 20.1 M | 17.1 M | 16.1 M | 15.2 M |
Historical Prices |
0.87 | 0.62 | 0.92 | 1.29 | 2.82 | 1.74 | 0.4 | 0.95 | 1.2 | 1.71 | 2.72 | 1.5 | 1.2 | 0.41 |
Net Income |
-4.71 M | -6.93 M | -8.71 M | -6.82 M | -7.39 M | -7.52 M | -7.43 M | -5.19 M | -5.95 M | -5.47 M | -1.7 M | 1.46 M | -870 K | -1.48 M |
Revenue |
8.63 M | 9.83 M | 8.81 M | 10.3 M | 5.44 M | 8.37 M | 9.62 M | 11.3 M | 10.5 M | 9.49 M | 10.3 M | 10 M | 8.65 M | 8.38 M |
Cost of Revenue |
2.2 M | 3.03 M | 3.91 M | 3.99 M | 1.82 M | 2.66 M | 5.19 M | 4.31 M | - | - | - | - | - | - |
Gross Profit |
6.43 M | 6.79 M | 4.9 M | 6.31 M | 3.62 M | 5.72 M | 4.43 M | 6.97 M | 6.31 M | 6.44 M | 6.7 M | 6.81 M | 5.59 M | 5.36 M |
Operating Income |
-6.76 M | -7.11 M | -8.83 M | -7.38 M | -7.45 M | -4 M | -8 M | -5.23 M | -6.51 M | -3.06 M | -790 K | 1.09 M | -520 K | -1.22 M |
Interest Expense |
60.3 K | 126 K | 54.6 K | -16.4 K | -24.8 K | -10.4 K | -7.23 K | -4.93 K | -5.09 K | -5.35 K | 2.67 K | 70.8 K | 176 K | 132 K |
EBITDA |
-6.72 M | -7.04 M | -8.76 M | -7.3 M | -7.41 M | -3.74 M | -5.58 M | -4.66 M | -6.35 M | -2.96 M | -694 K | 1.18 M | -425 K | -1.12 M |
Operating Expenses |
13.2 M | 13.9 M | 13.7 M | 13.7 M | 11.1 M | 9.72 M | 10.9 M | 12.2 M | 12.8 M | 9.5 M | 7.49 M | 5.73 M | 6.11 M | 6.59 M |
General and Administrative Expenses |
12.3 M | 13.1 M | 12.5 M | 12.7 M | 10.8 M | 9.53 M | 10.6 M | 11.9 M | 11.5 M | 9.4 M | 7.4 M | 5.53 M | 5.93 M | 6.45 M |
All numbers in USD currency
Quarterly Income Statement Milestone Scientific
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
82.3 M | 82 M | 81.9 M | 78 M | 80 M | 80 M | 79.7 M | 75.8 M | 73.7 M | 72.3 M | 72.1 M | 69.3 M | 71 M | 70.4 M | 69 M | 68.1 M | 69.6 M | 69.2 M | 66.6 M | 64.1 M | 65.8 M | 56.7 M | 49.7 M | 49.4 M | 47.7 M | 45.4 M | 40.5 M | 33.8 M | 35.6 M | 35.3 M | 34.8 M | 33.2 M | 33.6 M | 32.4 M | 32 M | 30.4 M | 29.2 M | 26 M | 22.6 M | 21.7 M | 21.4 M | 22.4 M | 21.9 M | 21.4 M | 21.2 M | 20.2 M | 17.8 M | 17.7 M | 17.3 M | 16.7 M | 16.4 M | 16.5 M | 16.2 M | 16 M | 15.3 M | 15.5 M | 15.1 M | 15 M | 15.5 M |
Net Income |
-1.15 M | -1.48 M | -1.99 M | - | -1.46 M | 224 K | -1.44 M | - | -1.47 M | -2.22 M | -1.31 M | - | -1.97 M | -2.86 M | -1.92 M | - | -2.04 M | -2.7 M | -986 K | - | -1.49 M | -3.17 M | -1.6 M | - | -2.84 M | -1.04 M | -783 K | - | -4.39 M | -1.34 M | -1.87 M | - | -1.41 M | -1.48 M | -505 K | - | -1.7 M | -1.59 M | -750 K | - | -1.57 M | -2.07 M | -419 K | - | -358 K | -169 K | 195 K | - | 1.46 M | 74 K | 151 K | - | 15.2 K | -165 K | -355 K | - | -637 K | -298 K | -142 K |
Revenue |
2.36 M | 2.32 M | 2.23 M | - | 2.51 M | 1.85 M | 2.25 M | - | 2.06 M | 2.91 M | 2.6 M | - | 2.22 M | 1.65 M | 2.7 M | - | -69.9 K | -95.9 K | 1.3 K | - | - | - | 1.81 M | - | 49.1 K | 58.7 K | 9.56 K | - | 259 K | 78.6 K | 36.8 K | - | 2.85 M | 15.5 K | -44.4 K | - | -253 K | -57.9 K | -270 K | - | -711 K | -690 K | -358 K | - | -224 K | -213 K | 2.62 M | - | -212 K | -47.1 K | 2.49 M | - | - | -46.1 K | -78.1 K | - | -60 K | - | - |
Cost of Revenue |
719 K | 706 K | 585 K | - | 678 K | 443 K | 573 K | - | 556 K | 1.02 M | 708 K | - | 763 K | 968 K | 1.02 M | - | 748 K | 1.06 M | 1.12 M | - | 410 K | 55.6 K | 527 K | - | 524 K | 752 K | 619 K | - | 1.74 M | 1.02 M | 563 K | - | 1.04 M | 874 K | 1.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
1.64 M | 1.62 M | 1.65 M | - | 1.84 M | 1.41 M | 1.68 M | - | 1.5 M | 1.89 M | 1.89 M | - | 1.45 M | 681 K | 1.68 M | - | 1.36 M | 1.37 M | 1.8 M | - | 836 K | 112 K | 1.28 M | - | 1.38 M | 1.51 M | 1.3 M | - | -120 K | 1.41 M | 1.24 M | - | 1.81 M | 1.65 M | 2.29 M | - | 1.67 M | 1.58 M | 2.2 M | - | 1.67 M | 1.2 M | 1.84 M | - | 1.71 M | 1.59 M | 1.74 M | - | 1.77 M | 1.53 M | 1.68 M | - | 1.5 M | 1.47 M | 1.26 M | - | 1.15 M | 1.6 M | 1.55 M |
Operating Income |
-1.13 M | -1.48 M | -2 M | - | -1.47 M | -1.78 M | -1.47 M | - | -1.51 M | -2.28 M | -1.34 M | - | -2.01 M | -2.88 M | -1.91 M | - | -1.98 M | -2.87 M | -984 K | - | -1.48 M | -3.17 M | -1.61 M | - | -947 K | -1.11 M | -818 K | - | -4.55 M | -1.42 M | -2 M | - | -1.41 M | -1.55 M | -526 K | - | -1.57 M | -2.02 M | -943 K | - | -835 K | -1.41 M | -71.1 K | - | -162 K | 47.5 K | 329 K | - | 436 K | 1.46 M | 168 K | - | 51.6 K | -53.6 K | -233 K | - | -540 K | -262 K | -122 K |
Interest Expense |
- | 1.52 K | 3.27 K | - | 8.01 K | 21 K | 24.5 K | - | 30.6 K | 48.7 K | 23.3 K | - | 28 K | 3.55 K | -4.74 K | - | -4.61 K | -4.46 K | -2.54 K | - | -569 | -4.06 K | -4.21 K | - | -2.63 K | -2.56 K | -2.26 K | - | -1.78 K | -1.76 K | -1.7 K | - | -1.05 K | -1.02 K | -1.21 K | - | 846 | -1 K | 1.24 K | - | 1.04 K | - | 1.21 K | - | - | - | -475 | - | 5.55 K | 30 K | 34.6 K | - | 36.5 K | 63.3 K | 42.4 K | - | 35.6 K | 34.7 K | 19.4 K |
EBITDA |
-1.11 M | -1.47 M | -1.98 M | - | -1.46 M | -1.77 M | -1.45 M | - | -1.49 M | -2.26 M | -1.33 M | - | -2 M | -2.87 M | -1.9 M | - | -1.96 M | -2.86 M | -963 K | - | -1.46 M | -3.15 M | -1.57 M | - | -921 K | -1.08 M | -792 K | - | -4.2 M | -1.18 M | -1.74 M | - | -1.25 M | -1.52 M | -491 K | - | -1.5 M | -1.97 M | -921 K | - | -815 K | -1.4 M | -65.4 K | - | -150 K | 54.5 K | 333 K | - | 449 K | 1.47 M | 172 K | - | 66.1 K | -43.6 K | -228 K | - | -524 K | -251 K | -116 K |
Operating Expenses |
2.78 M | 3.1 M | 3.65 M | - | 3.31 M | 3.19 M | 3.14 M | - | 3.01 M | 4.17 M | 3.23 M | - | 3.47 M | 3.57 M | 3.6 M | - | 3.34 M | 4.24 M | 2.79 M | - | 2.31 M | 3.28 M | 2.89 M | - | 2.32 M | 2.61 M | 2.12 M | - | 4.43 M | 2.83 M | 3.24 M | - | 3.22 M | 3.2 M | 2.81 M | - | 3.24 M | 3.6 M | 3.14 M | - | 2.5 M | 2.61 M | 1.91 M | - | 1.87 M | 1.55 M | 1.41 M | - | 1.33 M | 1.38 M | 1.51 M | - | 1.45 M | 1.53 M | 1.49 M | - | 1.69 M | 1.86 M | 1.67 M |
General and Administrative Expenses |
2.74 M | 3.03 M | 3.26 M | - | 3.06 M | 2.87 M | 3.04 M | - | 2.82 M | 3.94 M | 3.07 M | - | 3.28 M | 3.28 M | 3.12 M | - | 2.97 M | 4.01 M | 2.75 M | - | 2.28 M | 3.16 M | 2.75 M | - | 2.31 M | 2.52 M | 2.11 M | - | 2.89 M | 2.82 M | 3.02 M | - | 3.21 M | 3.08 M | 2.71 M | - | 2.93 M | 3.29 M | 3 M | - | 2.48 M | 2.59 M | 1.9 M | - | 1.84 M | 1.52 M | 1.39 M | - | 1.32 M | 1.34 M | 1.39 M | - | 1.39 M | 1.49 M | 1.45 M | - | 1.7 M | 1.8 M | 1.62 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Milestone Scientific (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
AtriCure
ATRC
|
$ 29.85 | 1.05 % | $ 1.43 B |  USA |
 |
AngioDynamics
ANGO
|
$ 10.6 | -1.03 % | $ 433 M | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M | USA |
 |
Harvard Bioscience
HBIO
|
$ 0.47 | -4.15 % | $ 19.9 M | USA |
 |
Alcon
ALC
|
$ 77.32 | -1.5 % | $ 40.4 B |  Schweiz |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
ICU Medical
ICUI
|
$ 125.85 | -2.28 % | $ 3.1 B | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
InfuSystem Holdings
INFU
|
$ 9.31 | -0.85 % | $ 192 M | USA |
 |
iRhythm Technologies
IRTC
|
$ 113.0 | -1.46 % | $ 3.62 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 472.16 | -1.48 % | $ 169 B | USA |
 |
The Cooper Companies
COO
|
$ 69.92 | -2.24 % | $ 13.9 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Glaukos Corporation
GKOS
|
$ 97.02 | -0.79 % | $ 4.7 B | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 159.36 | -0.17 % | $ 45.8 B | USA |
 |
Haemonetics Corporation
HAE
|
$ 59.92 | 0.72 % | $ 3.02 B | USA |
 |
electroCore
ECOR
|
$ 6.14 | -3.0 % | $ 33.9 K | USA |
 |
Masimo Corporation
MASI
|
$ 175.49 | -0.01 % | $ 9.35 B | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
$ 11.56 | -2.12 % | $ 28 M | USA |
 |
Repro Med Systems
KRMD
|
$ 4.28 | -0.7 % | $ 198 M | USA |
 |
Baxter International
BAX
|
$ 17.4 | -3.36 % | $ 8.93 B | USA |
 |
BioLife Solutions
BLFS
|
$ 18.36 | 1.16 % | $ 846 M | USA |
 |
Nephros
NEPH
|
$ 3.5 | -7.89 % | $ 36.4 M | USA |
 |
ResMed
RMD
|
$ 230.84 | -0.68 % | $ 33.7 B | USA |
 |
Retractable Technologies
RVP
|
$ 0.71 | 2.62 % | $ 21.3 M | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
Merit Medical Systems
MMSI
|
$ 69.95 | 2.61 % | $ 4.14 B | USA |
 |
Envista Holdings Corporation
NVST
|
$ 24.61 | -3.26 % | $ 4.13 B | USA |
 |
STAAR Surgical Company
STAA
|
$ 18.84 | 2.45 % | $ 934 M | USA |
 |
Stereotaxis
STXS
|
$ 1.89 | 0.27 % | $ 172 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 107.32 | -0.87 % | $ 4.79 B | USA |
 |
OraSure Technologies
OSUR
|
$ 2.97 | -3.88 % | $ 218 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 108.06 | 1.43 % | $ 2.45 B | USA |
 |
Utah Medical Products
UTMD
|
$ 63.28 | 1.02 % | $ 230 M | USA |
 |
Pro-Dex
PDEX
|
$ 48.46 | 3.5 % | $ 159 M | USA |
 |
Microbot Medical
MBOT
|
$ 2.69 | -1.47 % | $ 27.4 M |  Israel |
 |
West Pharmaceutical Services
WST
|
$ 235.46 | 1.89 % | $ 17 B | USA |
 |
Repligen Corporation
RGEN
|
$ 114.2 | 0.39 % | $ 6.36 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 11.54 | -2.2 % | $ 2.3 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 21.57 | 1.27 % | $ 1.45 B | USA |
 |
STERIS plc
STE
|
$ 214.57 | 1.05 % | $ 21.2 B | USA |